(Reuters) -Sanofi won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said on...
(Reuters) - Regeneron (NASDAQ:REGN) Pharmaceuticals reported better-than-expected revenue aided by sales from its COVID-19 antibody outside the United States and strong demand for...
Regeneron (NASDAQ:REGN) reported Q1 EPS of $11.49, $1.45 better than the analyst estimate of $10.04. Revenue for the quarter came in at $2.97 billion versus the consensus estimate...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
2022 has started on a different note. After a pandemic-driven market that saw growth stocks soar and indices continue to climb, the onset of a number of factors has slowed the...
Wall Street has been on high alert in recent months as an array of headwinds has roiled investors—and markets. For starters, following the interest rate hike of March 16, the...
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 20.36 | 20.40 | 18.70 | +1.53 | +8.13% | 5.12M | NASDAQ | |||
| 82.31 | 84.07 | 81.07 | -0.16 | -0.19% | 22.86M | NYSE | |||
| 92.65 | 93.89 | 89.52 | +1.49 | +1.63% | 109.22M | NASDAQ | |||
| 168.97 | 169.49 | 166.96 | +1.15 | +0.69% | 5.77M | NASDAQ | |||
| 101.70 | 102.24 | 99.16 | +1.82 | +1.82% | 1.51M | NASDAQ | |||
| 107.82 | 108.55 | 104.39 | +2.24 | +2.12% | 760.16K | NYSE | |||
| 4.10 | 4.20 | 3.93 | +0.1400 | +3.54% | 292.24K | NASDAQ | |||
| 8.71 | 8.95 | 8.71 | -0.190 | -2.13% | 13.36K | NASDAQ | |||
| 17.19 | 17.19 | 16.97 | +0.04 | +0.26% | 1.56K | NASDAQ | |||
| 96.55 | 97.35 | 95.59 | +0.49 | +0.51% | 69.77K | NASDAQ | |||
| 5.27 | 5.35 | 5.05 | +0.10 | +1.93% | 1.14M | NASDAQ | |||
| 101.84 | 102.42 | 98.89 | +1.75 | +1.75% | 940.66K | NYSE | |||
| 322.72 | 326.61 | 318.68 | -0.16 | -0.05% | 378.90K | NASDAQ | |||
| 1.09 | 1.09 | 0.99 | +0.103 | +10.44% | 407.03K | NASDAQ | |||
| 188.59 | 190.34 | 186.17 | +1.67 | +0.89% | 350.39K | NYSE |